Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine

Inclusion Criteria: * Eligible to receive REPEVAX® or COVAXIS® vaccine, in accord with German recommendations for a booster dose of acellular pertussis vaccine at 9-17 years of age. * Signed and dated informed consent or assent form (as applicable) that is obtained prior to the first study intervention. * Judged to be in good health on the basis of reported medical history and history-directed physical examination. * Plans to remain in the study area for the length of the trial. * The participant and a parent or legal guardian can read, write, and understand the documents and all are mentally competent to give assent and consent. * If female, not known or suspected to be pregnant at the time of enrollment into the study and is not planning pregnancy during participation in this trial. * Either prior participation in study 371-03/01 (Group 1 - 6th Dose Pertussis Vaccine Group) or a documented history of 3 doses of tetanus, diphtheria and whole-cell pertussis vaccine in infancy plus at least one subsequent dose of pertussis vaccine in their 2nd through 7th year of life (Group 2 - 5th Dose Pertussis Vaccine Group). * Has access to a telephone. * Oral temperature \< 38.0ºC. Exclusion Criteria: * Pregnancy or nursing a child * Known or suspected primary or acquired disease of the immune system (conditions suspected of having an immunologic component such as autoimmune diseases \[e.g. rheumatoid arthritis or inflammatory bowel disease\] will not be excluded unless they meet exclusion criterion 3 or 5). * Malignancy, allergy immunotherapy, or receiving immunosuppressive therapy (participants who are taking topical and inhaled steroids could be included in the study as would participants on a "short course" of oral steroids, -\<7 days, as long as there are not two courses within the previous two weeks prior to vaccination). * Receipt of any pertussis, diphtheria or tetanus-containing vaccines within the past 3 years. * Any unstable significant underlying chronic disease, including (but not limited to) malignancy, cardiopulmonary disease, renal, endocrinologic, hematologic or hepatic dysfunction. * Known impairment of neurologic function or currently active seizure disorder or currently requiring medication for seizures. * Personal history of physician-diagnosed or laboratory-confirmed pertussis disease within the last 2 years. * Receipt of blood products or immunoglobulin within the previous 3 months. * Known or suspected allergy to any of the vaccines or vaccine components intended for use in the study. * Daily use of non-steroidal anti-inflammatory drugs. * Receipt of any vaccine or investigational product within the 30 days prior to enrollment, or planning to receive another vaccine within 28 days after receiving study vaccine. * Chemical dependency (e.g. alcoholism or intravenous drug use but not including nicotine or caffeine), based on investigator judgment. * Known or suspected acute infectious respiratory illness at the time of vaccination with active symptoms and signs including one or more of the following: rhinorrhea, new cough, pharyngitis, respiratory problems (e.g. wheezing, shortness of breath). * Any condition which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine. * History of immediate anaphylaxis, encephalopathy within 7 days, or seizure within 3 days of receiving diphtheria, tetanus, or pertussis vaccine. * Planned participation in another interventional clinical trial during the present trial period (participation in a related study to evaluate immune responses to this study's vaccination is permitted). * Thrombocytopenia or bleeding disorder that would pose a contraindication to an intramuscular (IM) vaccination.